Comparing Psyence Biomedical (PBM) and Its Competitors

Psyence Biomedical (NASDAQ:PBM) is one of 617 publicly-traded companies in the “MED – BIOMED/GENE” industry, but how does it compare to its peers? We will compare Psyence Biomedical to similar companies based on the strength of its analyst recommendations, dividends, profitability, risk, institutional ownership, earnings and valuation.

Analyst Ratings

This is a summary of recent recommendations for Psyence Biomedical and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Psyence Biomedical	1	0	0	0	1.00
Psyence Biomedical Competitors	5605	12101	37483	1146	2.61

As a group, “MED – BIOMED/GENE” companies have a potential upside of 58.85%. Given Psyence Biomedical’s peers stronger consensus rating and higher probable upside, analysts clearly believe Psyence Biomedical has less favorable growth aspects than its peers.

Profitability

This table compares Psyence Biomedical and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Psyence Biomedical	N/A	N/A	N/A
Psyence Biomedical Competitors	-1,425.14%	-743.10%	-28.26%

Insider and Institutional Ownership

77.4% of Psyence Biomedical shares are owned by institutional investors. Comparatively, 51.2% of shares of all “MED – BIOMED/GENE” companies are owned by institutional investors. 3.6% of Psyence Biomedical shares are owned by company insiders. Comparatively, 13.7% of shares of all “MED – BIOMED/GENE” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

Psyence Biomedical has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500. Comparatively, Psyence Biomedical’s peers have a beta of 0.99, indicating that their average share price is 1% less volatile than the S&P 500.

Earnings & Valuation

This table compares Psyence Biomedical and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Psyence Biomedical	N/A	$1.01 million	0.67
Psyence Biomedical Competitors	$960.92 million	-$46.52 million	11.59

Psyence Biomedical’s peers have higher revenue, but lower earnings than Psyence Biomedical. Psyence Biomedical is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Psyence Biomedical peers beat Psyence Biomedical on 8 of the 13 factors compared.

Psyence Biomedical Company Profile

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company’s lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.